Scribe Therapeutics, Inc. — Form 4
Filed July 28, 2026 · analyzed by the Insider Agent
4
▲ Likely positive
significance 78/100
What the filing says
Director Aghazadeh Behzad (SCTX) bought 2.4M shares (~$36.3M) on the open market (44% of holdings). Open-market insider purchase — historically a bullish signal.
Why this rating
Open-market insider purchase — historically a bullish signal.
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.